160 likes | 279 Vues
Cancer vaccines have emerged as a promising approach in the treatment and prevention of hematologic B-cell malignancies. This area of research addresses various challenges, including vaccine design, immune response elicitation, and patient stratification. By focusing on specific antigens and improving adjuvant technologies, advancements are being made in creating effective cancer immunotherapies. Understanding the nuances of B-cell malignancies, including pre-B cell acute lymphoblastic leukemia (ALL), is essential for optimizing vaccine strategies to enhance patient outcomes.
E N D